肌肉痉挛市场－全球产业规模、份额、趋势、机会和预测，按药物类型、给药途径、配销通路、地区和竞争细分，2020 年至 2030 年

2024 年全球肌肉痉挛市场价值为 41.1 亿美元，预计到 2030 年将达到 55.3 亿美元，复合年增长率为 5.03%。全球肌肉痉挛市场是更广泛的医疗保健产业中一个充满活力且不断发展的领域，专注于解决肌肉痉挛这一复杂的医疗状况。肌肉痉挛的特征是肌肉不自主收缩和僵硬，通常由多发性硬化症、脑性麻痹或脊髓损伤等神经系统疾病引起。多年来，随着神经系统疾病发病率的不断上升、医疗技术的进步以及人口老化日益加剧，该市场经历了显着的成长和创新。

关键市场驱动因素

神经系统疾病发生率上升

主要市场挑战

治疗费用高昂

主要市场趋势

提高认识和教育

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：全球肌肉痉挛市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类型（巴氯芬、肉毒桿菌、地西泮、丹曲林钠等）
  • 依给药途径（口服、肌肉注射、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 依药物类型
  • 依给药途径
  • 按配销通路
  • 按地区

第五章：亚太地区肌肉痉挛市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类型
  • 依给药途径
  • 按配销通路
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第六章：欧洲肌肉痉挛市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第七章：北美肌肉痉挛市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第八章：南美肌肉痉挛市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第九章：中东和非洲肌肉痉挛市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 12 章：全球肌肉痉挛市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Novartis AG
• Beximco Pharmaceuticals Ltd.
• Zydus Cadila
• Porex Corporation
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd

第 15 章：策略建议

第16章调查会社について・免责事项

Global Muscle Spasticity Market was valued at USD 4.11 Billion in 2024 and is expected to reach USD 5.53 Billion in the forecast period with a CAGR of 5.03% through 2030. The global muscle spasticity market is a dynamic and evolving sector within the broader healthcare industry, focused on addressing the complex medical condition of muscle spasticity. Muscle spasticity is characterized by involuntary muscle contractions and stiffness, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, or spinal cord injuries. This market has witnessed significant growth and innovation over the years, driven by the increasing prevalence of neurological disorders, advancements in medical technology, and a growing aging population.

Key Market Drivers

Rising Incidence of Neurological Disorders

The rising incidence of neurological disorders is a pivotal driver behind the burgeoning growth of the global muscle spasticity market. Neurological conditions such as multiple sclerosis (MS), cerebral palsy, spinal cord injuries, stroke, and Parkinson's disease frequently manifest with muscle spasticity, characterized by involuntary muscle contractions and stiffness that significantly impair patients' quality of life.

Multiple sclerosis, in particular, has seen a notable increase in prevalence. According to the World Health Organization (WHO), over 1.8 million people worldwide are affected by MS, with a higher incidence among young adults and females. This autoimmune disease affects the central nervous system and is a leading contributor to muscle spasticity. As the number of MS cases continues to rise, so does the demand for effective treatments to alleviate the debilitating symptoms associated with the condition. Pharmaceutical companies have responded by developing a range of medications aimed at providing relief and improving the daily lives of patients.

Key Market Challenges

High Treatment Costs

High treatment costs pose a significant hurdle in the global muscle spasticity market, impeding the accessibility of care for individuals grappling with this debilitating condition. Muscle spasticity, characterized by involuntary muscle contractions and stiffness, often results from neurological disorders like multiple sclerosis, cerebral palsy, and spinal cord injuries. While treatment options have advanced, the soaring expenses associated with these therapies present a considerable challenge for both patients and healthcare systems. One of the primary issues driving the high treatment costs is the development and production of specialized medications and medical devices tailored for muscle spasticity management. Pharmaceutical companies invest heavily in research and development to create effective drugs that target the condition's symptoms and underlying causes. These innovative treatments, while offering hope for improved patient outcomes, often come with a substantial price tag, making them financially burdensome for many patients.

Key Market Trends

Increasing Awareness and Education

Increasing awareness and education have become instrumental in propelling the global muscle spasticity market forward. In recent years, concerted efforts by advocacy groups, healthcare organizations, and pharmaceutical companies have led to a significant uptick in public understanding and recognition of this debilitating condition. Muscle spasticity, a common symptom in neurological disorders like multiple sclerosis, spinal cord injuries, and stroke, was often overlooked or misunderstood in the past. However, with increased awareness campaigns and educational initiatives, both patients and healthcare providers are now more informed about its prevalence, symptoms, and available treatment options.

Key Market Players

• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Novartis AG
• Beximco Pharmaceuticals Ltd.
• Zydus Cadila
• Porex Corporation
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Muscle Spasticity Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Muscle Spasticity Market, By Drug Type:

• Baclofen
• Botulinum Toxin
• Diazepam
• Dantrolene Sodium
• Others

Muscle Spasticity Market, By Route of Administration:

• Oral
• Intramuscular
• Others

Muscle Spasticity Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Muscle Spasticity Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Muscle Spasticity Market.

Available Customizations:

Global Muscle Spasticity Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Muscle Spasticity Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others)
  • 4.2.2. By Route of Administration (Oral, Intramuscular, Others)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Drug Type
  • 4.3.2. By Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Muscle Spasticity Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type
  • 5.2.2. By Route of Administration
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Muscle Spasticity Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Type
      • 5.3.1.2.2. By Route of Administration
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Muscle Spasticity Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Type
      • 5.3.2.2.2. By Route of Administration
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Muscle Spasticity Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Type
      • 5.3.3.2.2. By Route of Administration
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Muscle Spasticity Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Type
      • 5.3.4.2.2. By Route of Administration
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Muscle Spasticity Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Type
      • 5.3.5.2.2. By Route of Administration
      • 5.3.5.2.3. By Distribution Channel

6. Europe Muscle Spasticity Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Muscle Spasticity Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Muscle Spasticity Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Muscle Spasticity Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Muscle Spasticity Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Type
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Muscle Spasticity Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Type
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. North America Muscle Spasticity Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Muscle Spasticity Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Muscle Spasticity Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Muscle Spasticity Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel

8. South America Muscle Spasticity Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Muscle Spasticity Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Muscle Spasticity Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Muscle Spasticity Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Muscle Spasticity Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Muscle Spasticity Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Muscle Spasticity Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Muscle Spasticity Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Muscle Spasticity Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Ipsen Pharma
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Allergan
• 14.3. Acorda Therapeutics, Inc.
• 14.4. Merz Pharma
• 14.5. Novartis AG
• 14.6. Beximco Pharmaceuticals Ltd.
• 14.7. Zydus Cadila
• 14.8. Porex Corporation
• 14.9. Teva Pharmaceutical Industries Ltd
• 14.10. Sun Pharmaceutical Industries Ltd

15. Strategic Recommendations

16. About Us & Disclaimer